{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:40:20Z","timestamp":1756449620569,"version":"3.44.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"DOI":"10.1007\/s10554-025-03452-4","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:53:05Z","timestamp":1751849585000},"page":"1627-1630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Back to normal: super-response to mavacamten in a patient with obstructive hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"41","author":[{"given":"Tobia","family":"Albertini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain M.","family":"Bernheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annina A. Studer","family":"Bruengger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"doi-asserted-by":"publisher","unstructured":"Maron BJ, Rowin EJ, Ambe SP, Maron MS (2022) Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research, Am. J. Med., vol. 135, no. 10, pp. 1244\u20131246, Oct. https:\/\/doi.org\/10.1016\/j.amjmed.2022.05.006","key":"3452_CR1","DOI":"10.1016\/j.amjmed.2022.05.006"},{"doi-asserted-by":"publisher","unstructured":"Olivotto I et al (2020) Sep., Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet, vol. 396, no. 10253, pp. 759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","key":"3452_CR2","DOI":"10.1016\/S0140-6736(20)31792-X"},{"unstructured":"CAMZYOS\u00ae (mavacamten) Dosing Guide| Safety Profile. Accessed: Feb. 24, 2025. [Online]. Available: https:\/\/www.camzyoshcp.com\/dosing-guide","key":"3452_CR3"},{"doi-asserted-by":"publisher","unstructured":"Wigle ED, Rakowski H, Kimball BP, Williams WG (Oct. 1995) Hypertrophic cardiomyopathy. Circulation 92(7):1680\u20131692. https:\/\/doi.org\/10.1161\/01.CIR.92.7.1680","key":"3452_CR4","DOI":"10.1161\/01.CIR.92.7.1680"},{"doi-asserted-by":"publisher","unstructured":"Green EM et al (Feb. 2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(6273):617\u2013621. https:\/\/doi.org\/10.1126\/science.aad3456","key":"3452_CR5","DOI":"10.1126\/science.aad3456"},{"doi-asserted-by":"publisher","unstructured":"Hegde SM et al (2021) Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy, J. Am. Coll. Cardiol., vol. 78, no. 25, pp. 2518\u20132532, Dec. https:\/\/doi.org\/10.1016\/j.jacc.2021.09.1381","key":"3452_CR6","DOI":"10.1016\/j.jacc.2021.09.1381"},{"doi-asserted-by":"publisher","unstructured":"Saberi S et al (Feb. 2021) Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy. Circulation 143(6):606\u2013608. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052359","key":"3452_CR7","DOI":"10.1161\/CIRCULATIONAHA.120.052359"},{"doi-asserted-by":"publisher","unstructured":"Moravsky G et al (2013) Myocardial Mechanical Remodeling after Septal Myectomy for Severe Obstructive Hypertrophic Cardiomyopathy, J. Am. Soc. Echocardiogr., vol. 26, no. 8, pp. 893\u2013900, Aug. https:\/\/doi.org\/10.1016\/j.echo.2013.05.012","key":"3452_CR8","DOI":"10.1016\/j.echo.2013.05.012"},{"doi-asserted-by":"publisher","unstructured":"D\u0105browski M et al (2019) Reduction of left ventricular mass, left atrial size, and N-terminal pro\u2013B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy, Pol. Heart J. Kardiologia Pol., vol. 77, no. 2, Art. no. 2. https:\/\/doi.org\/10.5603\/KP.a2018.0242","key":"3452_CR9","DOI":"10.5603\/KP.a2018.0242"},{"doi-asserted-by":"publisher","unstructured":"Wang A et al (Dec. 2024) Association between age or duration of diagnosis in obstructive hypertrophic cardiomyopathy and response to Mavacamten treatment: exploratory analysis of the EXPLORER-HCM trial. J Card Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2024.10.449","key":"3452_CR10","DOI":"10.1016\/j.cardfail.2024.10.449"},{"doi-asserted-by":"publisher","unstructured":"Giudicessi JR et al (2024) Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy, Mayo Clin. Proc., vol. 99, no. 2, pp. 341\u2013343, Feb. https:\/\/doi.org\/10.1016\/j.mayocp.2023.11.019","key":"3452_CR11","DOI":"10.1016\/j.mayocp.2023.11.019"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-025-03452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-025-03452-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-025-03452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:22:38Z","timestamp":1756448558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10554-025-03452-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":11,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1007\/s10554-025-03452-4","relation":{},"ISSN":["1875-8312"],"issn-type":[{"type":"electronic","value":"1875-8312"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}